Tango Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Tango Therapeutics's estimated annual revenue is currently $12.9M per year.
- Tango Therapeutics received $55.0M in venture funding in March 2017.
- Tango Therapeutics's estimated revenue per employee is $155,000
- Tango Therapeutics's total funding is $55M.
- Tango Therapeutics has 83 Employees.
- Tango Therapeutics grew their employee count by 38% last year.
- Tango Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Tango Therapeutics?
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango's programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango's success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.keywords:N/A
Number of Employees
Employee Growth %
|Janid Ali||Vice President, Biochemistry|
|David Guerin||Director, Chemistry|
|Patrick McCarren||Associate Director, Computational Chemistry|
|John Maxwell||Vp Chemistry|
|Kevin Cottrell||Director Of Medicinal Chemistry|
|Yi Yu||Associate Director - Computational Biology|
|Douglas Whittington||Director of Structural Biology|
|Caroline Proulx-Lafrance||Director Project Management|
|Lina Gu||Associate Director|
Tango Therapeutics News
Narayan comes to Lexington, MA-based Accent from Tango Therapeutics, where he was chief business officer for the past two years.
Narayan most recently served as CBO at Tango Therapeutics. Prior to Tango, Narayan was a VP and head of transactions at Johnson ...
Dr. Narayan was most recently Chief Business Officer of Tango Therapeutics, where he was responsible for business development, finance ...
Tango Therapeutics Funding
|2017-03-31||$55.0M||A||Third Rock Ventures||Article|
Tango Therapeutics Executive Hires
|2017-12-07||Shakti Narayan||Chief Business Officer||Article|
|2018-05-11||Alan Huang||Chief Scientific Officer||Article|